RCUS — Arcus Biosciences, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1724521 ·
Last close
$28.19
Market Cap
$3.55B
52W High
$31.74
52W Low
$21.84
ADV30
1,436,193
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 17,000,000 | — | -134,000,000 | -128,000,000 | 997,000,000 | 201,000,000 | 473,000,000 |
| Dec 2025 | 33,000,000 | — | -114,000,000 | -106,000,000 | 1,139,000,000 | 222,000,000 | 508,000,000 |
| Sep 2025 | 26,000,000 | — | -142,000,000 | -135,000,000 | 974,000,000 | 238,000,000 | 538,000,000 |
| Jun 2025 | 160,000,000 | — | -8,000,000 | 0 | 1,075,000,000 | 248,000,000 | 526,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-482,000,000
Investing CF
$66,000,000
Financing CF
$488,000,000
CapEx
$-4,000,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.30
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,485,000,000
Inventory
—
Receivables
$16,000,000
ST Investments
$759,000,000
EBIT TTM
$-345,000,000
Pretax Income TTM
$-353,000,000
Interest Exp TTM
$8,000,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$236,000,000
EBITDA
$-389,000,000
Free Cash Flow
$-156,000,000
Enterprise Value
$2,955,545,344
Total Cash
$822,000,000
Total Debt
$232,000,000
Shares Out
125,773,162
Trailing EPS
$-3.17
Book Value
$4.17
ROE
-70.0%
ROA
-23.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 247,000,000 | -386,000,000 | -353,000,000 | 1,139,000,000 | 508,000,000 | — | -482,000,000 |
| Dec 2024 | 258,000,000 | -310,000,000 | -283,000,000 | 1,150,000,000 | 665,000,000 | — | -170,000,000 |
| Dec 2023 | 117,000,000 | -340,000,000 | -307,000,000 | 1,095,000,000 | 633,000,000 | — | -306,000,000 |
| Dec 2022 | 112,000,000 | -280,000,000 | -267,000,000 | 1,345,000,000 | 688,000,000 | — | 438,000,000 |
TTM Snapshot
Revenues TTM
$113,000,000
NetIncome TTM
$-228,000,000
OpCashFlow TTM
$0
Assets (Latest)
$1,150,000,000
Forward EPS
$-3.10
Max Pain — expiry 2026-10-16
max pain strike: $20.00 · spot: $28.19 · call oi: 2,053 · put oi: 674
Expected Move to 2026-10-16:
±$7.90
(28.02%) —
implied range
$20.29 –
$36.09
· ATM straddle on $30.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OGN | Organon & Co. | $3.56B | $13.55 | — |
| LEGN | Legend Biotech Corp | $3.59B | $18.55 | — |
| ALMS | ALUMIS INC. | $3.49B | $28.25 | — |
| KNSA | Kiniksa Pharmaceuticals International, plc | $3.44B | $74.34 | — |
| IDYA | IDEAYA Biosciences, Inc. | $3.42B | $35.50 | — |
News headlines (Yahoo Finance, 1h cache)
Arcus Biosciences Announces New Employment Inducement Grants
2026-07-27 20:35 · Yahoo
SMMT's Q2 Loss Wider Than Expected, Ivonescimab Development in Focus
2026-07-24 13:10 · Yahoo
Summit Therapeutics Inc (SMMT) Q2 2026 Earnings Call Highlights: Strong Cash Position and ...
2026-07-24 05:01 · Yahoo
SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study
2026-07-23 14:31 · Yahoo
Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients
2026-07-22 20:35 · Yahoo
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
2026-07-22 20:30 · Yahoo
Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates
2026-07-21 20:05 · Yahoo
An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run
2026-07-13 23:29 · Yahoo
Bristol-Myers Squibb (BMY) Joins Arcus Biosciences to Test a New Two-Drug Kidney Cancer Combination
2026-07-01 21:35 · Yahoo
New Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan
2026-07-01 15:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.